REGENXBIO to Participate in Upcoming Investor Conferences
Get Alerts RGNX Hot Sheet
Join SI Premium – FREE
Leerink Partners 2024 Global Biopharma Conference
Date:
Location:
1x1 investor meetings only
Barclays 26th Annual Global Healthcare Conference
Fireside Chat:
Gene Therapy Regulatory Path in Rare Diseases Panel:
Location:
UBS Virtual CNS Day
Fireside Chat: Monday, March 18, 2024 at
Location: Virtual
A live webcast of the fireside chat at the Barclays conference can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.
Contacts:
Dana Cormack
Corporate Communications
[email protected]
Investors:
339-970-2843
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302084950.html
SOURCE REGENXBIO Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Mud Springs Trail System Opens Near Moab, Expanding World-Class Mountain Biking Opportunities
- Cryptocurrency News Today: BNB Chain Hits 40% of Global Stablecoin Volume While Pepeto Presale Nears $11 Million
- $9.9 Million Revenue for First Half of 2026, a 25% Increase Over Same Period in 2025 for Emerging AI and Robotics Developer Baird Medical Investment Holdings (Nasdaq: BDMD)
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share